PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
Հիմնական հեղինակներ: | VAN DIJK M., RAB M., VAN OIRSCHOT B., BOS J., DERICHS C., RIJNEVELD A., CNOSSEN M., NUR E., BIEMOND B., BARTELS M., JANS J., VAN SOLINGE W., SCHUTGENS R., VAN WIJK R., VAN BEERS E. |
---|---|
Ձևաչափ: | Հոդված |
Լեզու: | English |
Հրապարակվել է: |
Wiley
2022-08-01
|
Շարք: | HemaSphere |
Առցանց հասանելիություն: | http://journals.lww.com/10.1097/01.HS9.0000872868.40573.13 |
Նմանատիպ նյութեր
-
P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
: Myrthe van Dijk, և այլն
Հրապարակվել է: (2023-08-01) -
P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
: M. J. van Dijk, և այլն
Հրապարակվել է: (2022-06-01) -
5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
: M.J. van Dijk, և այլն
Հրապարակվել է: (2023-04-01) -
Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
: Myrthe J. vanDijk, և այլն
Հրապարակվել է: (2024-06-01) -
P1492: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
: M. Rab, և այլն
Հրապարակվել է: (2022-06-01)